Arrowhead Pharmaceuticals Company Profile (NASDAQ:ARWR)

About Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ARWR
  • CUSIP: N/A
  • Web: www.arrowheadpharma.com
Capitalization:
  • Market Cap: $290.86 million
  • Outstanding Shares: 74,772,000
Average Prices:
  • 50 Day Moving Avg: $3.77
  • 200 Day Moving Avg: $2.25
  • 52 Week Range: $1.20 - $6.86
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.89
  • P/E Growth: -1.30
Sales & Book Value:
  • Annual Revenue: $22.73 million
  • Price / Sales: 12.80
  • Book Value: $1.21 per share
  • Price / Book: 3.21
Profitability:
  • EBITDA: ($47,970,000.00)
  • Net Margins: -201.84%
  • Return on Equity: -46.73%
  • Return on Assets: -34.08%
Debt:
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 3.84%
  • Quick Ratio: 3.84%
Misc:
  • Average Volume: 1.24 million shs.
  • Beta: 1.94
  • Short Ratio: 10.59
 

Frequently Asked Questions for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) posted its earnings results on Thursday, August, 3rd. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.06. The firm earned $9.34 million during the quarter, compared to analysts' expectations of $5.29 million. Arrowhead Pharmaceuticals had a negative net margin of 201.84% and a negative return on equity of 46.73%. View Arrowhead Pharmaceuticals' Earnings History.

When will Arrowhead Pharmaceuticals make its next earnings announcement?

Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, December, 12th 2017. View Earnings Estimates for Arrowhead Pharmaceuticals.

Where is Arrowhead Pharmaceuticals' stock going? Where will Arrowhead Pharmaceuticals' stock price be in 2017?

5 brokers have issued 1 year price objectives for Arrowhead Pharmaceuticals' shares. Their forecasts range from $2.00 to $2.00. On average, they anticipate Arrowhead Pharmaceuticals' share price to reach $2.00 in the next twelve months. View Analyst Ratings for Arrowhead Pharmaceuticals.

Who are some of Arrowhead Pharmaceuticals' key competitors?

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the folowing people:

  • Douglass B. Given M.D., Ph.D., Chairman of the Board
  • Christopher Richard Anzalone Ph.D., President, Chief Executive Officer, Director
  • Kenneth Allen Myszkowski, Chief Financial Officer
  • Bruce D. Given M.D., Chief Operating Officer
  • Patrick O'Brien, General Counsel
  • Michael S. Perry Ph.D., Lead Independent Director
  • Mauro Ferrari Ph.D., Independent Director
  • Edward W. Frykman, Independent Director

How do I buy Arrowhead Pharmaceuticals stock?

Shares of Arrowhead Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arrowhead Pharmaceuticals' stock price today?

One share of Arrowhead Pharmaceuticals stock can currently be purchased for approximately $3.89.


MarketBeat Community Rating for Arrowhead Pharmaceuticals (NASDAQ ARWR)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  144 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  249
MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Arrowhead Pharmaceuticals (NASDAQ:ARWR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $2.00 (48.59% downside)
Consensus Price Target History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Price Target History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Analysts' Ratings History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/25/2017Cantor FitzgeraldReiterated RatingHold$2.00MediumView Rating Details
9/18/2017William BlairUpgradeMarket Perform -> OutperformHighView Rating Details
9/13/2017Chardan CapitalReiterated RatingNeutralMediumView Rating Details
8/4/2017Jefferies Group LLCReiterated RatingHold$2.00HighView Rating Details
7/28/2017Piper Jaffray CompaniesReiterated RatingHold$2.00MediumView Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Earnings by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Earnings History by Quarter for Arrowhead Pharmaceuticals (NASDAQ ARWR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/12/2017($0.10)N/AView Earnings Details
8/3/2017Q3 2017($0.13)($0.07)$5.29 million$9.34 millionViewListenView Earnings Details
5/3/2017Q2 2017($0.12)($0.08)$4.19 million$8.99 millionViewListenView Earnings Details
2/6/2017Q117($0.20)($0.17)$13.24 million$4.37 millionViewListenView Earnings Details
8/9/2016Q316($0.37)($0.32)$0.05 million$39.58 millionViewN/AView Earnings Details
5/10/2016Q216($0.37)($0.35)$0.26 million$0.04 millionViewListenView Earnings Details
2/9/2016Q1($0.41)($0.32)$0.29 million$0.04 millionViewN/AView Earnings Details
12/14/2015Q415($0.39)($0.42)$0.14 million$0.04 millionViewListenView Earnings Details
8/4/2015Q315($0.38)($0.27)$0.11 million$0.12 millionViewN/AView Earnings Details
5/11/2015Q214($0.35)($0.33)$110.00 million$43.75 millionViewListenView Earnings Details
2/9/2015Q114($0.32)($0.41)$0.24 million$0.17 millionViewN/AView Earnings Details
11/25/2014Q413($0.25)($0.33)$0.04 million$0.04 millionViewN/AView Earnings Details
8/12/2014Q313($0.22)($0.22)$0.04 million$0.04 millionViewN/AView Earnings Details
5/6/2014Q2 2014($0.18)($0.31)$0.05 million$0.04 millionViewN/AView Earnings Details
2/4/2014Q4($0.18)($0.33)ViewN/AView Earnings Details
12/18/2013Q4($0.23)($0.43)ViewListenView Earnings Details
5/9/2013Q2 2013($0.41)ViewN/AView Earnings Details
2/13/2013Q1 2013($0.33)ViewN/AView Earnings Details
12/20/2012Q4 2012($0.43)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
2017 EPS Consensus Estimate: ($0.21)
2018 EPS Consensus Estimate: ($0.68)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.22$0.22$0.22
Q2 20172($0.16)($0.11)($0.14)
Q3 20173($0.15)($0.13)($0.14)
Q4 20173($0.18)($0.10)($0.15)
Q1 20181($0.11)($0.11)($0.11)
Q2 20181($0.19)($0.19)($0.19)
Q3 20181($0.19)($0.19)($0.19)
Q4 20181($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Insider Ownership Percentage: 4.57%
Institutional Ownership Percentage: 20.61%
Insider Trades by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Institutional Ownership by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Insider Trades by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/14/2016Douglas B. GivenDirectorSell12,000$6.72$80,640.00View SEC Filing  
8/23/2016Kenneth Allen MyszkowskiCFOSell6,900$8.00$55,200.00View SEC Filing  
8/22/2016Kenneth Allen MyszkowskiCFOSell13,100$8.00$104,800.00View SEC Filing  
12/30/2015Kenneth Allen MyszkowskiCFOSell23,347$6.13$143,117.11View SEC Filing  
10/28/2015Mauro FerrariDirectorBuy400$7.62$3,048.00View SEC Filing  
10/9/2015Mauro FerrariDirectorBuy1,900$6.19$11,761.00View SEC Filing  
1/5/2015David L LewisInsiderSell15,000$8.01$120,150.00View SEC Filing  
10/15/2014Christopher Richard AnzaloneCEOBuy16,000$6.32$101,120.00View SEC Filing  
10/1/2014Charles MckenneyDirectorSell2,500$14.70$36,750.00View SEC Filing  
9/30/2014David L LewisInsiderSell15,000$15.02$225,300.00View SEC Filing  
9/26/2014Douglas B GivenDirectorSell2,000$15.24$30,480.00View SEC Filing  
6/9/2014Charles MckenneyDirectorSell22,000$14.32$315,040.00View SEC Filing  
2/12/2014Kenneth Allen MyszkowskiCFOSell16,000$18.77$300,320.00View SEC Filing  
2/7/2014Edward W FrykmanDirectorSell3,148$15.98$50,305.04View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Latest Headlines for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Source:
Loading headlines, please wait.

Social

Chart

Arrowhead Pharmaceuticals (ARWR) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.